Cerivastatin, a new potent synthetic HMG Co-A reductase inhibitor: Effect of 0.2 mg daily in subjects with primary hypercholesterolemia

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 2, Issue 1, 1997, Pages 7-16

  Stein, E ^a   Sprecher, D ^a   Allenby, K S ^a   Tosiello, R L ^a   Whalen, E ^a   Ripa, S R ^a  

^a Metabolic and Atherosclerosis Research Center   (United States)

Author keywords

cerivastatin; HMG CoA reductase inhibitors; hypercholesterolemia

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLU LIKE SYNDROME; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SINUSITIS; THORAX PAIN;

EID: 0030914257     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/107424849700200102     Document Type: Article

References (30)